DELRAY BEACH, Fla. , Sept. 17, 2024 /PRNewswire/ -- The human microbiome market is set to grow significantly, reaching USD 4,206 million by 2030 from USD 814.
6 million in 2024, driven by a robust CAGR of 31.5%. Key factors propelling this growth include advancements in microbiome sequencing, collaborative research efforts, and a surge in startups and SMEs exploring microbiome-based solutions.
However, challenges such as complex regulations, high commercialization costs, and slow patient adoption could impact market expansion. AI-driven technologies are transforming microbiome-based therapies by enabling personalized healthcare through precise data analysis. Notable players in this field include Biomica, which leverages AI for developing microbiome therapies.
The market is characterized by a high number of startups and SMEs, significant investments in R&D, and a growing focus on personalized medicine. Challenges include the high cost of developing and commercializing microbiome drugs, evidenced by the discontinuation of Finch Therapeutics' fecal microbiota transplant. Opportunities lie in the rising demand for personalized medicine, with increasing awareness and advancements in microbiome diagnostics.
The market is segmented by products, diseases, and regions, with North America leading in market share, followed by Europe and the fast-growing Asia Pacific region. Key market players include Seres Therapeutics, Ferring Pharmaceuticals, and BiomeBank, among others..
